drugset / Trial / NCT01935479

A Phase I Study of AK159 in Healthy Postmenopausal Women

NCT01935479

Phase 1 Completed 170 enrolled Asahi Kasei Therapeutics Corporation
RandomizedParallel-groupDouble-blindBasic science

Summary

The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.

Timeline

Start
2013-08
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator MN-10-T Unknown Subcutaneous
Subject Teriparatide Protein / enzyme biologic Other

Indications